1
Clinical Trials associated with H3N2v MN 2010/AA ca live attenuated influenza vaccine(NIAID)Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H3N2v (6-2) AA ca Recombinant (A/Minnesota/11/2010 (H3N2v) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H3N2v Disease
This study will evaluate the safety and immunogenicity of the H3N2v MN 2010/AA ca live attenuated influenza vaccine (H3N2v LAIV) in healthy children and adults, 6 to 26 years old.
100 Clinical Results associated with H3N2v MN 2010/AA ca live attenuated influenza vaccine(NIAID)
100 Translational Medicine associated with H3N2v MN 2010/AA ca live attenuated influenza vaccine(NIAID)
100 Patents (Medical) associated with H3N2v MN 2010/AA ca live attenuated influenza vaccine(NIAID)
100 Deals associated with H3N2v MN 2010/AA ca live attenuated influenza vaccine(NIAID)